With the improvement of the living standards of the people in our country，The continuous development of the aging structure of the population，The number one killer in "silver incidence" and "rich disease" -cardiovascular and cerebrovascular disease，has quietly become a place for soldiers in my country's pharmaceutical market。And cardiovascular and cerebrovascular diseases have the characteristics of long -term medication，Coupled with the gradual implementation of the new medical reform policy，Make domestic companies glimpse this territory for a long time。
"A Big Step" of Tzuoshi Internationalization
A few days ago，Tianjin Tashem Pharmaceutical Co., Ltd. wholly-owned subsidiary-Tasham North American Pharmaceuticals today announced the signing with ICON (Aikon Clinical Research Co., Ltd.) and Parexel (Jingding Pharmaceutical Research and Development Co., Ltd.). Research cooperation stake betting appstake betting appintention。This indicates that Tiansi Fufang Danshen Di Wan became the first Chinese patent medicine after the completion of the US Food and Drug Administration (FDA) clinical trials in my country in 2010.，The launching preparation phase of the global phase III clinical research。icon is the fifth largest CRO company in the world，Focus on the strategic development of from the selection from compounds to phase I-IV clinical research、Management and project evaluation，Parexel is the world's leading biopharmaceutical service company，Facing the global pharmaceutical industry、Biotechnology industry and medical equipment industry provide a wide range of knowledge -based contract research、Medical Exchange and Consultation Services。Select cooperation with the internationally renowned CRO company for phase III clinical research，Invisible overseas registration for compound Danshen Di Wan adds a successful chip。
The international clinical research of compound Danshen Di Pills is the first compound Chinese medicine in China and the world in accordance with modern medical standards，major research projects performed under FDA IND (that is, obtaining clinical research approval)，It marks that the modern Chinese medicine research on traditional Chinese medicine has entered a new international stage，The ultimate goal is to establish international standards for the development and production of modern Chinese medicine，This is an unprecedented career。
stake online sports bettingTable 1: FDA approval process of compound Danshen drop pill
|
Time stage |
Related matters |
meaning |
|
1997 |
Formally applied through FDA IND |
Become the first compound Chinese medicine preparation to pass this approval in China |
|
1997-2007 |
After ten years of unremitting efforts and a large number Stake Sports Bettingstake betting appof follow -up research,Starting phase II clinical research in 2007 |
The product level and management level of the enterprise have been greatly improved,Preparation for phase II clinical research |
|
December 2009 |
Completed strict phase II clinical trials in 15 clinical centers in the United States |
Fully proves its effectiveness and safety,Become the first phase II clinical trial applied for FDA in my country,and the Chinese patent medicine that is about to enter the phase III clinical trial |
|
July 22 to 23, 2010 |
Hold two applicants communication meetings with the FDA,Summary of clinical clinical situation of compound Danshen Di Pills and related matters related to the phase III clinical plan |
Reflected the high attention of FDA for its prospects,FDA is very satisfied with the research results of phases II,Agree with phase III clinical research |
|
2011-2012 |
Task will be within two years,Establish 50 to 70 clinical trial centers in the world,Periodment of phase III clinical trial |
Lay the foundation for the phase III clinical trial |
Fourth Ring Street "Holding Group" Development
Four Ring Pharmaceuticals announced in July，Signing an agreement with Shandong Buchang Pharmaceutical Co., Ltd. ("Shandong Buchang") under the indirect wholly -owned subsidiary Smart Baskets，Xiang Shandong Bukou sold 50%of the equity of Wan Sheng Pharmaceutical at a premium of RMB 637.5 billion。This cooperation means that as the leading cardiovascular and cerebrovascular drug supplier in the country-Four Ring Medicine，The leading enterprise of traditional Chinese medicine and pharmaceuticals -Shandong Buchang jointly develops Chinese cardiovascular and cerebrovascular drugs, Chinese medicine market，The core position of local enterprises in the cardiovascular and cerebrovascular drug market。
The pharmaceutical sector "Bougang Pharmaceutical" of Bao Chang Group is a family focusing on the research and development of Chinese medicine patent drugs、Production、Domestic companies sold，It has a rich and mature product line in the Chinese patent medicine market，And there is a good sales layout in third -tier cities, counties and towns，Sales network crosses covers 15,000 hospitals and 130,000 retail pharmacies across the country;，It is at the same time、A strategic sales network in second -tier cities; the combination of the two can be described as complementary and long。Cardiovascular and cerebrovascular drugs are the main sales parts of steppe and fourth ring ring。According to relevant data, it shows，The sales of cardiovascular and cerebrovascular drugs of Four Ring Pharmaceuticals in 2010 accounted for more than 80%of the overall sales，Where，Kelinao has accounted for half of the overall sales; the Danhong injection solution of Shandong Buchang accounts for more than 90%of its overall sales。
|
Enterprise |
Drug |
|
stake online sports bettingFour Rings Medicine |
stake betting appKlinao (GM name: Malaysian acid cinnamon Qitt injection) |
|
|
Anjieli (General name: Malaysian Ninato Zitt injection) |
|
|
Chuanqing (GM name: Sichuan Ligurazine) |
|
|
Quao (General name: hydrolysis of brain protein for injection) |
|
|
Aotosid (General name: Sodium Saloginic Saloginoside Injection Sodium Injection) |
|
Building Group |
Danhong injection |
|
|
Stable granation |
|
|
Brain Heart |
|
|
Cumin Capsule |
|
|
Crown Heart Shusong Capsules |
